Kanker-actueel Prostate cancer: Dendritic cell therapy shows promising results in Phase I study of 20 hormone-resistant prostate cancer patients.

Startpagina

Contact | Disclaimer | Sitehulp

Sitemap | Video's

Patiëntenervaringen | Lotgenotencontact

Forum |

Onze Sponsors

Cancer Types

Regular

Complementary

Coaching

Donations

Questions

Cancer News

Addresses

Prevention

Recipes

Artikelen

Dendritic cell therapy what does that mean? Article updated April 19, 2011

Dendritic cell therapy educational video with better scores on the word and image. Even videos with experience stories can be viewed here. Article updated June 22, 2011

Patient Experiences with dendritic cell (videos)

General: Prof. Dr. Yvette van Kooyk tells about immunology and states such as dendritic cells and how they work in radio casa luna. Listen to the program. Article updated June 22, 2011

General dendritic cell: Dr.. Figdor KWF receives a prize of 2 million euros for research into the effects of dendritic cell therapy in cancer. Article updated June 22, 2011

Article on success and promise of dendritic cell therapy. Article updated June 22, 2011

Report from our visit to Robert Gorter in Cologne including the protocol, when supply and dendritic cell can and can not seem sensible. And what it all costs time and money. Article updated June 22, 2011

ODE in the August 2006 issue featured an interview with Dr. Robert Gorter about the promising potential of dendritic cell therapy in various cancers.

breast cancer: breast tumours of advanced breast cancer gives promising results-3 year survival goes to 16%. Article update 22 June 2011

Dendritic cell therapy. Vaccination against cancer. Nijmegen research stimulates immune system in cultured cells. Article updated June 22, 2011

Adenocarcinoma: Oncovax, a form of auto vaccination, gives significantly better results in survival, survival time and time to recurrence in patients with adenocarcinoma stadum II. No significant difference in stage III colon cancer. Article updated June 22, 2011

Adenocarcinoma: Pharmaceutical company Intracel spans lawsuit to be successful vaccine against cancer Oncovax called on the Dutch market. Oncovax car is kind of vaccination, so with their own tumor vaccine is made and purest form of dendritic cell therapy. Article posted in August 2004.

Cancer: Dendritic cell therapy in three separate laboratory studies prove positive effect on immune responses and values might be important for metastatic cancer. Article posted in June 2005.

Dendritic cell therapy in general: Dendritic cell therapy accompanied by super paramagnetic iron oxide formulation or (111) In-oxine = thin iron particles gives better control of dendritic cell therapy works so well Nijmegen researchers report in a study report. Article posted November 2005

Brain tumors and dendritic cell: an overview of recent developments and important studies. Articles updated June 22, 2011

Bibliography of studies with dendritic cell therapy. Updated June 22, 2011

Leukemia: Dendritic cell therapy shows promising effects to give in some leukemia patients with AML - Acute Myeloid Leukemia. Thus Belgian phase I / II trial in 10 patients. Article posted August 5, 2010

Dendritic cell and melanoma: Dendritic cell therapy combined with hyperthermia significantly better results than without hyperthermia. Article updated June 22, 2011

Dendritic cell and melanoma: Dendritic cell therapy combined with hyperthermia in animal studies in mice with melanoma cells, 60% result - complete regression of tumors - compared with 0% in three different control groups, respectively. group with no treatment, hyperthermia only group, only group dendritic cells. Article posted May 2005

Dendritic cell and melanoma: Dendritic cell therapy combined with hyperthermia doubles survival (from 6 to 13 months) for patients with advanced melanoma. Article posted October 2007

Mesothelioma and dendritic cell therapy: encouraging results from Phase I trials of dendritic cell therapy in mesothelioma - asbestos cancer, released at ASCO 2010. Article updated June 9, 2010

Research and dendritic cell: UMC receives millions for research into dendritic cell therapy. Article updated April 19, 2011

PDT = Photodynamic Therapy and Dendritic cell: A combination of local PDT followed by dendrische cell therapy in mice remarkable remissions which the individual treatments did nothing. Article posted November 2006

Prostate cancer and dendritic cell: Dendritic cell therapy shows promising results in Phase I study of 20 hormone-resistant prostate cancer patients. Article posted in August 2005

Prostate cancer: Provenge as immunotherapeutic agent in the form of dendritic cell therapy in hormone resistant prostate cancer provides significantly longer survival. 3-year survival is 38% and improves median survival by 4 months (20%). A highly significant result. Phase III study shows. FDA approval for Provenge now. Article updated June 22, 2011

Prostate cancer and dendritic cell: Dendritic cell therapy shows promising results in Phase I study of 20 hormone-resistant prostate cancer patients. Article posted in August 2005

June 22, 2011: Please read the recently added information about Dr. Robert Gorter and Medical Center in Cologne this information: My experience with dr.Robert Gorter and the Medical Center Cologne. A warning

And click here for addresses of clinics in Germany, where dendritic cell therapy is given .

September 29, 2005: Source: British Journal of Cancer (2005) 93, 749-756. doi: 10.1038/sj.bjc.6602761 Published online 30 August 2005

Dendritic cell therapy in prostate cancer patients shows promising initial results from Phase I study in 20 hormone-resistant prostate cancer patients in Norway. Hormone Resistant means that these patients despite hormone therapy, such as Zoladex and Casodex, progression of their illness. In English refers to dendritic cells taken from prostate cancer cells combined with the body's own "mRNA from allogeneic prostate cancer cell lines (DU145, LNCaP and PC-3)". Thanks to MB explained to us what this means: RNA is the carrier of the genetic code of many disease-causing viruses such as HIV, SARS, hepatitis. Currently there are working groups that are trying to use RNA as a switch to a genetic defect correction. Human genes consist of DNA and RNA.
Dr. Robert Gorter no walks this path. Robert Gorter works from monocytes, immature dendritic cells where it is. Robert Gorter will work with the Newcastle virus in addition to dendritic cell

Interestingly, this study found good and interesting enough to publish in The British Journal of Cancer and the VU in Amsterdam soon be a trial of dendritic cell therapy in hormone-resistant prostate cancer patients to start. Dendritic cell therapy is a form of treatment that is definitely looks interesting and seems to give results, even within the mainstream oncology. Here is the abstract of the study and the article from Norway published in The British Journal of Cancer.

Immunotherapy with dendritic cells transfected allotumour mRNA in androgen-resistant prostate cancer Patients

LJ Mu1, 2, JA Kyte1, Kvalheim2 G, S Aamdal3, Dueland3 S, M Hauser4, H Hammerstad2, Waehre5 H, N and G Raabe6 Gaudernack1
1Section for Immunotherapy, The Norwegian Radium Hospital, University of Oslo, Montebello, Oslo 0310, Norway 3Department of Clinical Cancer Research, The Norwegian Radium Hospital, University of Oslo, Montebello, Oslo 0310, Norway
4Department of Radiology, The Norwegian Radium Hospital, University of Oslo, Montebello, Oslo 0310, Norway
5Department of Surgery, The Norwegian Radium Hospital, University of Oslo, Montebello, Oslo 0310, Norway
6Department of Oncology, The Norwegian Radium Hospital, University of Oslo, Montebello, Oslo 0310, Norway

Correspondence to: Dr G Gaudernack, E-mail: @ gustav.gaudernack labmed.uio.no

Received 5 May 2005, revised 29 June 2005, accepted 2 August 2005, published online 30 August 2005

Here, we present results from a clinical trial employ a new vaccination method Using dendritic cells (DCs) transfected with mRNA from allogeneic prostate cancer cell lines (DU145, LNCaP and PC-3). In all, 20 patients were enrolled and 19 have completed vaccination. Each patient received at least four weekly injections with 2 "107 transfected DCs Either intranodally or intradermally. Safety and feasibility of vaccination were Determined. Immune responses were Measured as delayed-type hypersensitivity and by in vitro immunoassays Including ELISPOT and T-cell proliferation in pre-and postvaccination peripheral blood samples. Serum prostate-specific antigen (PSA) levels and bone scans were monitored. No toxicity or serious adverse events related to vaccination were observed. A total of 12 patients a specific immune response to Developed tumor mRNA-transfected DCs. In total, 13 patients showed a Decrease in log slope PSA. This effect was strengthened by booster vaccination. Clinical outcome was significantly related to immune responses (n = 19, P = 0.002, r = 0.68). Vaccination with mRNA transfected DCs is safe and results in cellular immune responses specific for antigens encoded by mRNA derived from the prostate cancer cell lines. That the observation of some vaccination Patients Affected the PSA level suggests this approach That May become useful as a treatment modality for prostate cancer patient.